These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2868364)

  • 1. LHRH analogues in prostatic cancer.
    Lancet; 1986 Feb; 1(8478):445-6. PubMed ID: 2868364
    [No Abstract]   [Full Text] [Related]  

  • 2. Orchidectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer.
    Williams G
    Lancet; 1986 Jan; 1(8473):157. PubMed ID: 2867375
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R; Lachance R; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of LHRH agonists in the treatment of advanced cancer of the prostate].
    Fretin J
    Arch Esp Urol; 1990; 43(6):647-9. PubMed ID: 2151155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dramatic aggravation of prostatic cancer at the onset of treatment with an LHRH agonist].
    Boumier P; Koeger AC; Camus JP
    Presse Med; 1985 May; 14(21):1200-1. PubMed ID: 3158996
    [No Abstract]   [Full Text] [Related]  

  • 6. Medical or surgical orchidectomy.
    Parmar H; Edwards LE; Phillips RH; Charlton C; Lightman SI
    BMJ; 1991 May; 302(6787):1272. PubMed ID: 1828382
    [No Abstract]   [Full Text] [Related]  

  • 7. Disease flare induced by luteinising hormone releasing hormone analogues in cancer patients.
    Deghenghi R; Misset JL
    Lancet; 1984 Jun; 1(8389):1302. PubMed ID: 6145013
    [No Abstract]   [Full Text] [Related]  

  • 8. Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer.
    Parmar H; Edwards L; Phillips RH; Allen L; Lightman SL
    Br J Urol; 1987 Mar; 59(3):248-54. PubMed ID: 2952213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deslorelin. D-Trp-LHRH-PEA, LHRH agonist analogue, Somagard.
    Drugs R D; 1999 Dec; 2(6):420-2. PubMed ID: 10763456
    [No Abstract]   [Full Text] [Related]  

  • 10. Disease flare induced by D-Trp6-LHRH analogue in patients with metastatic prostatic cancer.
    Kahan A; Delrieu F; Amor B; Chiche R; Steg A
    Lancet; 1984 Apr; 1(8383):971-2. PubMed ID: 6143912
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats.
    Kovacs M; Schally AV
    Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12197-202. PubMed ID: 11593037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.
    Moorjani S; Dupont A; Labrie F; Lupien PJ; Gagné C; Brun D; Giguère M; Bélanger A; Cusan L
    J Clin Endocrinol Metab; 1988 Feb; 66(2):314-22. PubMed ID: 3276721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of advanced prostatic cancer with a gonadorelin agonist, dTrp6 LHRH. 41 cases].
    Steg A; Chiche R; Boccon-Gibod L; Debré B
    Presse Med; 1985 Nov; 14(40):2045-8. PubMed ID: 2934695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone analogs and prostatic cancer.
    Swanson LJ; Seely JH; Garnick MB
    Crit Rev Oncol Hematol; 1988; 8(1):1-26. PubMed ID: 2964939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer.
    Waxman J; Man A; Hendry WF; Whitfield HN; Besser GM; Tiptaft RC; Paris AM; Oliver RT
    Br Med J (Clin Res Ed); 1985 Nov; 291(6506):1387-8. PubMed ID: 2933122
    [No Abstract]   [Full Text] [Related]  

  • 16. New gonadotropin-releasing hormone glycolipids with direct antiproliferative activity and gonadotropin-releasing potency.
    Varamini P; Mansfeld FM; Giddam AK; Steyn F; Toth I
    Int J Pharm; 2017 Apr; 521(1-2):327-336. PubMed ID: 28232269
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparative study of a long acting luteinizing hormone releasing hormone agonist (Decapeptyl) and orchiectomy in the treatment of advanced prostatic cancer. Preliminary report.
    De Sy WA; de Meyer JM; Casselman J; De Smet R; Renders G; Schelfhout W; De Wilde P
    Acta Urol Belg; 1986; 54(2):221-9. PubMed ID: 2942015
    [No Abstract]   [Full Text] [Related]  

  • 18. Gonadotrophin hormone releasing analogues open new doors in cancer treatment.
    Waxman J
    Br Med J (Clin Res Ed); 1987 Oct; 295(6606):1084-5. PubMed ID: 2961401
    [No Abstract]   [Full Text] [Related]  

  • 19. [Endometriosis].
    Osuga Y
    Nihon Rinsho; 2006 Apr; 64 Suppl 4():112-5. PubMed ID: 16689294
    [No Abstract]   [Full Text] [Related]  

  • 20. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
    Gründker C; Völker P; Schulz KD; Emons G
    Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.